Bristol/Otsuka aripiprazole "approvable"
This article was originally published in Pharmaceutical Approvals Monthly
FDA deems Bristol-Myers Squibb/Otsuka's schizophrenia treatment aripiprazole (new proposed tradename Abilify) "approvable" August 30. The aripiprazole NDA was submitted October 31, 2001. The firms expect approval of the atypical antipsychotic before the end of 200
You may also be interested in...
"We're particularly concerned about the health care area right now because obviously that's driving everything now," says Tennessee AG Herbert Slatery III. He and CRN CEO Steve Mister spoke with HBW Insight about regulation of the consumer health marketplace with FDA suspending inspections of facilities operated by businesses manufacturing and marketing products subject to its oversight.
In addition to our daily in-depth coverage of key events relating to the coronavirus pandemic, we’re bringing you a periodic round-up of other significant developments.
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.